243 results about "Chronic sinusitis" patented technology

Embodiments of the present invention provide a method for treatment of respiratory disorders such as asthma, chronic obstructive pulmonary disease, and chronic sinusitis, including cystic fibrosis, interstitial fibrosis, chronic bronchitis, emphysema, bronchopulmonary dysplasia and neoplasia. The method involves administration, preferably oral, nasal or pulmonary administration, of anti-inflammatory and anti-proliferative drugs (rapamycin or paclitaxel and their analogues).

Chronic rhinosinusitis and other bacterial sinus conditions may be treated by applying a solvating system containing a surfactant to a bacterial biofilm in a nasal or sinus cavity, disrupting the biofilm, and applying a protective layer of a polymeric film-forming medical sealant.

Embodiments of the present invention provide a method for treatment of respiratory disorders such as asthma, chronic obstructive pulmonary disease, and chronic sinusitis, including cystic fibrosis, interstitial fibrosis, chronic bronchitis, emphysema, bronchopulmonary dysplasia and neoplasia. The method involves administration, preferably oral, nasal or pulmonary administration, of anti-inflammatory and anti-proliferative drugs (rapamycin or paclitaxel and their analogues) and an additive.

The present invention relates to new drug combinations which contain in addition to one or more PDE4-inhibitors at least one NSAID (=non-steroidal anti-inflammatory drug) (2), processes for preparing them and their use in treating in particular respiratory complaints such as for example COPD, chronic sinusitis and asthma.The invention particularly relates to those drug combinations which contain, in addition to one or more, preferably one PDE4 inhibitor of general formula 1wherein X is SO or SO2, but preferably SO, and whereinR1, R2, R3 and R4 have the meanings given in claim 1, at least one NSAID (2), the preparation thereof and the use thereof for the treatment of respiratory complaints.

In some aspects, the present invention provides methods treating a subject in need of treatment for chronic rhinosinusitis or nasal polyposis, the methods comprising administering a complement inhibitor such as a compstatin analog to the subject. In some embodiments, the complement inhibitor is administered intranasally, e.g., in a nasal spray.

The present invention relates to a compound represented by the formula (I),wherein all symbols are as defined in the description,a salt thereof, a solvate thereof, or a prodrug thereof, which has a leukotriene receptor antagonistic activity which is expected to be more effective than those of the leukotriene receptor antagonists currently used in clinical trials. Therefore, it is useful as an agent for the prevention and / or treatment of a leukotriene-mediated disease such as a respiratory diseases such as bronchial asthma, chronic obstructive pulmonary disease, pulmonary emphysema, chronic bronchitis, pneumonia (e.g. interstitial pneumonia etc.), severe acute respiratory syndrome (SARS), acute respiratory distress syndrome (ARDS), allergic rhinitis, sinusitis (e.g. acute sinusitis, chronic sinusitis, etc.), or the like, or as an expectorant or an antiitussive.

The present invention relates to a compound represented by the formula (I),wherein all symbols are as defined in the description,a salt thereof, a solvate thereof, or a prodrug thereof, which has a leukotriene receptor antagonistic activity which is expected to be more effective than those of the leukotriene receptor antagonists currently used in clinical trials. Therefore, it is useful as an agent for the prevention and / or treatment of a leukotriene-mediated disease such as a respiratory diseases such as bronchial asthma, chronic obstructive pulmonary disease, pulmonary emphysema, chronic bronchitis, pneumonia (e.g. interstitial pneumonia etc.), severe acute respiratory syndrome (SARS), acute respiratory distress syndrome (ARDS), allergic rhinitis, sinusitis (e.g. acute sinusitis, chronic sinusitis, etc.), or the like, or as an expectorant or an antiitussive.

A pharmaceutical aerosol is disclosed which is suitable for delivering an active compound to the mucosa of the nose, the osteomeatal complex or a paranasal sinus. The pressure of the aerosol is not constant, but pulsates at a frequency from about 10 to 90 Hz. The aerosol is further characterized in that it exhibits a low effective flow rate of less than about 5 liters per minute. The aerosol is, inter alia, suitable for the prevention, management, or treatment of a disease, symptom, or condition affecting the nose or the paranasal sinuses, such as acute and chronic sinusitis.

The invention discloses a Chinese medicinal composition for treating children chronic sinusitis. The oral taken medicine comprises the following active ingredients in part by weight: 10 to 20 parts of Chinese angelica, 10 to 20 parts of xanthium sibiricum, 10 to 20 parts of nutgrass galingale rhizome, 10 to 20 parts of weeping forsythia, 10 to 20 parts of wax gourd seed, 10 to 20 parts of Szechuan lovage rhizome, 10 to 20 parts of platycodon root, 10 to 20 parts of sargent gloryvine, 10 to 20 parts of heartleaf houttuynia herb, 10 to 20 parts of astragalus, 10 to 20 parts of biond magnolia flower, 10 to 20 parts of angelica dahurica, 10 to 20 parts of baical skullcap root, 10 to 20 parts of Mongolian dandelion herb, 10 to 20 parts of honeysuckle and 10 to 20 parts of fineleaf schizonepetaherb; the external application medicine comprises the following active ingredients in part by weight: 10 to 20 parts of honeysuckle, 10 to 20 parts of nutgrass galingale rhizome, 10 to 20 parts of borneol, 10 to 20 parts of mint, 10 to 20 parts of manchurian wildginger, 10 to 20 parts of chrysanthemum, 10 to 20 parts of safflower, 10 to 20 parts of bletilla striata, 10 to 20 parts of divaricate saposhnikovia root and 10 to 20 parts of frankincense. The Chinese medicinal composition makes a nasal part lesion subjected to benign simulation so as to clear the meridians, dispel blood block, accelerate blood smoothness and achieve an effect of strengthening body resistance and eliminating evil, and has a better clinical effect through combined treatment of oral administration and external application.

Chronic sinusitis is treated by the application of cold plasma or plasma-activated species to the infected mucosal surfaces through use of an endoscope having a steerable end which may be projected into the sinus cavities through the nasal cavity. The cold plasma is generated at either the distal end of the endoscope with a power source by application of a power, or at the distal end by gas and electrical connections extending through the endoscope. The cold plasma or plasma-activated species act to destroy bacterial cells but not eukaryotic cells.

The invention provides for a proteomic approach for identification of specific bacterial protein profiles that may be used in the development of methods for the diagnosis of bacterial chronic sinusitis. The invention provides for methods for determining the presence of pathogenic bacteria in the upper respiratory tract of a subject using protein profiles of the pathogenic bacteria. The invention also provides for methods of diagnosing a bacterial infection of the upper respiratory tract of a subject using protein profiles of a pathogenic bacteria. In addition, the invention provides for devices, immunoassays and kits for identifying pathogenic bacteria in the upper respiratory tract.

The invention relates to a pharmaceutical composition with effects of awakening consciousness, clearing away heat and toxic material, eliminating dampness and discharging pus and a preparation method thereof. The pharmaceutical composition is prepared by the following bulk drugs according to proportioning by weight: 80-320 parts of indian bread, 80-320 parts of frosythia fruit, 80-320 parts of pilose asiabell root, 80-320 parts of belamcanda rhizome, 80-320 parts of biond magnolia flower, 80-320 parts of grassleaved sweetflag rhizome, 80-320 parts of white atractylodes rhizome, 80-320 parts of tangerine peel, 50-200 parts of Chinese yam, 50-200 parts of cocklebur fruit, 50-200 parts of red peony root, 80-320 parts of dahurian angelica root, 50-200 parts of trichosanthes root, 50-200 parts of balloonflower root, 50-200 parts of liquorice and 50-200 parts of chuanxiong rhizome and is processed into clinically accepted tablets, capsules or granules through extracting, refining and other processes. The invention has the effects of awakening consciousness, clearing away heat and toxic material and eliminating dampness and discharging pus, is generally used for nasosinusitis syndrome or stagnated heat of lung channel of nose therapy and can be also used for throat swelling and pain; and the invention is usually used for acute nasosinusitis, acute episode of chronic nasosinusitis and acute faucitis nowadays.

The invention provides for a proteomic approach for identification of specific bacterial protein profiles that may be used in the development of methods for the diagnosis of bacterial chronic sinusitis. The invention provides for methods for determining the presence of pathogenic bacteria in the upper respiratory tract of a subject using protein profiles of the pathogenic bacteria. The invention also provides for methods of diagnosing a bacterial infection of the upper respiratory tract of a subject using protein profiles of a pathogenic bacteria. In addition, the invention provides for devices, immunoassays and kits for identifying pathogenic bacteria in the upper respiratory tract.

The invention discloses a traditional Chinese herbal preparation for treating chronic nasosinusitis, which consists of gypsum, honeysuckle, chrysanthemum, ligusticum wallichii, radix angelicae, mint, dried tangerine, figwort root, spina gleditsiae, radices sileris, radix rehmanniae, angelica sinensis, pollen, magnolia flower, Siberian cocklour fruit, platycodon grandiflorum, radix bupleuri, radixscutellariae, herba pogostemonis, radix puerariae, bighead atractylodes rhizome and liquorice, the medicines are composited to generate a synergistic effect of all the medicine efficacies, and the preparation has the effects of opening the inhibited lung-energy, dispelling pathogenic wind, clearing liver fire, cooling and activating blood, eliminating stagnation and discharging pus. The traditional Chinese herbal preparation adopts the pharmacological basis on treating chronic nasosinusitis that: by aiming at the etiological pathology of the chronic nasosinusitis, the traditional Chinese herbal preparation prevents bacteria, diminish inflammation, avoid allergic reaction, improve immunity of the organism and microcirculation, and promote tissue cell repair. The preparation of the invention not only is in accordance with the principle of medicine and health syndrome differentiation and treatment in China, but also is supported by modern pharmological study, so the curative effect is obvious; and the preparation has no toxic or side effect, stable long-term effect and convenience for taking, and is worth being popularized.